Study shows advantages of cellular agriculture
Novel foods derived from cell culture instead of animals reduce the environmental impact of diets, water and land use by 80%, report Finnish researchers.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
EMA delays Valneva vaccine approval
/in News/by Thomas GabrielczykThe approval of Valneva’s Corona vaccine is delaying. The European Medicines Agencys CHMP requested additional data.
Mimetas BV participating in 325m cancer funding
/in News/by Thomas GabrielczykOrgan-on-chip disease model specialist Mimentas BV participates in a 325m funding to accelerate preclinical cancer R&D in the Netherlands.
Hansa Biopharmas imlifidase advances to Phase III testing
/in News/by Thomas GabrielczykThe US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharmas imlifidase in anti-GBM disease.
GSK acquires Sierra Oncology for 1.9bn
/in News/by Thomas GabrielczykGlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.
Scientists print 3D cancer model
/in News/by Thomas GabrielczykA 3D tumour model developed by scientists enables drug screening in metastases
Affimed prices public offering to finance NK cell trials
/in News/by Thomas GabrielczykFollowing phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.
GeNeuro finds biologic against post-COVID syndrome
/in News/by Thomas GabrielczykSwiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.
Catalent swallows VMIC Ltd
/in News/by Thomas GabrielczykCatalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.
AXA launches 440 m private equity healthcare strategy
/in News/by Thomas GabrielczykAXA IM Alts, has launched a Global Health Strategy following a 18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.